Noteworthy is the recent results from a phase 1/2 vaccination study combining PD-L1 and indoleamine-2,3-dioxygenase (IDO)-derived peptides in combination with the anti-PD-1 monoclonal antibody nivolumab in patients with malignant melanoma (22). This evidence concerns the gene CD274 and melanoma.